Capricor Therapeutics, Inc. (CAPR)
7.83
-0.18
(-2.25%)
USD |
NASDAQ |
Oct 09, 16:00
7.80
-0.03
(-0.38%)
After-Hours: 20:00
Capricor Therapeutics Cash from Operations (Quarterly) : -31.49M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -31.49M |
| March 31, 2026 | -29.25M |
| December 31, 2025 | -23.57M |
| September 30, 2025 | -19.69M |
| June 30, 2025 | -20.12M |
| March 31, 2025 | -6.434M |
| December 31, 2024 | -14.80M |
| September 30, 2024 | -11.64M |
| June 30, 2024 | -12.29M |
| March 31, 2024 | -1.268M |
| December 31, 2023 | -11.59M |
| September 30, 2023 | -8.795M |
| June 30, 2023 | -9.418M |
| March 31, 2023 | 4.210M |
| December 31, 2022 | -6.902M |
| September 30, 2022 | -5.686M |
| June 30, 2022 | -6.542M |
| March 31, 2022 | 24.05M |
| December 31, 2021 | -5.628M |
| September 30, 2021 | -3.338M |
| June 30, 2021 | -4.514M |
| March 31, 2021 | -3.329M |
| December 31, 2020 | -3.842M |
| September 30, 2020 | -2.978M |
| June 30, 2020 | -2.017M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.218M |
| December 31, 2019 | -1.785M |
| September 30, 2019 | -1.651M |
| June 30, 2019 | -1.777M |
| March 31, 2019 | -1.608M |
| December 31, 2018 | -3.771M |
| September 30, 2018 | -2.982M |
| June 30, 2018 | -3.691M |
| March 31, 2018 | -3.418M |
| December 31, 2017 | -2.667M |
| September 30, 2017 | -3.190M |
| June 30, 2017 | -3.698M |
| March 31, 2017 | -4.676M |
| December 31, 2016 | -4.578M |
| September 30, 2016 | -3.912M |
| June 30, 2016 | -4.884M |
| March 31, 2016 | -4.181M |
| December 31, 2015 | -3.643M |
| September 30, 2015 | -3.844M |
| June 30, 2015 | -3.326M |
| March 31, 2015 | -2.981M |
| December 31, 2014 | -2.869M |
| September 30, 2014 | -2.901M |
| June 30, 2014 | -2.193M |
| March 31, 2014 | 10.50M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| ARS Pharmaceuticals, Inc. | -60.93M |
| SELLAS Life Sciences Group, Inc. | -7.588M |
| Sionna Therapeutics, Inc. | -22.22M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Cytokinetics, Inc. | -159.84M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -48.76M |
| Cash from Financing (Quarterly) | -4.243M |
| Free Cash Flow | -129.78M |
| Free Cash Flow Per Share (Quarterly) | -0.6454 |
| Free Cash Flow to Equity (Quarterly) | -107.31M |
| Free Cash Flow to Firm (Quarterly) | -37.39M |
| Free Cash Flow Yield | -31.58% |